Contacts

Track record

MolMed has a proven track record in cell and gene therapy and in obtaining grants. Cell therapy can include genetic manipulation as in the TK platform, MolMed’s proprietary cell therapy - based on genetically engineered donor T cells where the production of retroviral vectors is performed in bioreactors and the transduction of donor T cells and expansion of transduced cells are in closed systems.
This technology has opened the door to bone marrow transplants even in leukaemia patients that do not have a fully compatible donor and is currently in Phase III clinical development.

Cell therapy experience includes a number of therapies developed and  produced on behalf of the San Raffaele Foundation in Italy, such as haematopoietic stem cells for transplantation, Duchenne Muscular Dystrophy treatment with the development of large-scale production of human mesoangioblasts from muscle tissue for clinical use, the treatment of melanoma with tumour-associated peptide extraction processed from a specific melanoma cell line, and the in vitro production of dendritic cells isolated from melanoma patients and stimulated with tumour-associated peptides.

Other therapies produced on behalf of the San Raffaele Foundation are the positive selection of human CD34+ haematopoietic progenitor cells to stimulate revascularisation, for infusion in patients with refractory angina pectoris and IL-10 immunotherapy for patients undergoing haematopoietic stem cell transplantation.

In gene therapy our track record includes the “one shot “ ADA-SCID therapy to cure severe combined immunodeficiency caused by Adenosine Deaminase (ADA)  deficiency and the treatment of two other rare genetic diseases, Wiskott-Aldrich Syndrome (WAS) and Metachromatic Leukodystrophy (MLD), both produced on behalf of the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET, Italy).

In the field of gene and cell therapy MolMed has obtained grants from the European Commission’s FP6 Framework Programme such as:

  • SKINTHERAPY  (project number 512073)
  • CONSERT  (project number 005242)

and from the FP7 Framework Programme such as: 

  • ATTRACT ( project number 238.778) 
  • PERSIST ( project number 222.878)
  • OPTISTEM (project number 223098).

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Share capital € 20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159